LEADNCT04403165
Locus-coeruleus Function in Normal Elderly and AD Risk
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 8 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Results posted: Nov 6, 2026 Show 4 more changesShow less
- Eligibility criteria expanded, about 16 words
- Primary endpoints: 8 to 10
- Enrollment target: 30 to 34
- Secondary endpoint revised
- Notable Primary endpoints revised (8)v9
- Notable Eligibility criteria shortened, about 68 wordsv7
- Minor Trial status: Recruiting to Completed
- Primary and study completion dates changed from estimate of Aug 31, 2024 to Mar 26, 2024
- Site details revised at 2 of 2 sites
- Notable Primary and study completion dates: Aug 2023 to Aug 31, 2024v5
Show 2 earlier versionsHide 2 earlier versions
- Notable Primary and study completion dates: Aug 2022 to Aug 2023v4
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 7 more changesShow less
- Primary and study completion dates moved earlier to Aug 2022
- Eligibility criteria expanded, about 58 words
- Primary endpoints: 4 to 8
- Study sites: 0 to 2
- Start date changed from estimate of Jul 2021 to Aug 6, 2020
- Interventions: Lumbar Puncture (LP) (Procedure), MRB PET-MR scan (Procedure), nocturnal polysomnography (NPSG) (Other) to Lumbar Puncture (LP) (Procedure), Nocturnal polysomnography (NPSG) (Procedure), PET-MR measurement with a norepinephrine transporter…
- Secondary endpoints expanded, about 6 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Methylreboxetine (MRB)-LC Mean Standardized Uptake Value Ratio (SUVR) Values
Timeframe: Visit 4 (1-4 weeks after LP that occurred on day 14)
Total Rapid Eye Movement (REM) Duration (Min)
Timeframe: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of Time Spent in REM Sleep
Timeframe: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of REM Runs That Are Less Than 5 Minutes
Timeframe: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of REM Runs That Are Greater Than or Equal to 5 Minutes
Timeframe: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of REM Runs That Are Greater Than or Equal to 10 Minutes
Timeframe: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of Correct Responses on the Picture Test
Timeframe: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Number of Sleep Spindles That Occur Per Minute During the N2 Stage of Sleep (N2 Spindle Density)
Timeframe: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Mean Psychomotor Vigilance Test (PVT) Reaction Time
Timeframe: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Picture Test Response Time
Timeframe: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Secondary (1)
Levels of Hyperphosphorylated Tau (P-Tau)
Arms and interventions
Cognitively Normal (CN) Older AdultsExperimental
Procedures: Nocturnal polysomnography (NPSG), Lumbar Puncture (LP)
Other: PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]Omethylreboxetine ([11C]MRB)
Behavioral: Psychomotor Vigilance Task (PVT)
Sites
2 sites in 1 country